EGFR and adenocarcinoma: While stratifying adenocarcinoma patients into EGFR-mutant and wild-type groups, who were under EGFR-TKI and chemotherapies before diseases progression, respectively, we observed that CEAIn prognostic power was evident only in the EGFR-mutant group but not in the wild-type group.